
Sign up to save your podcasts
Or


Michael Crackower, PhD, Chief Scientific Officer of Ventus Therapeutics, and Jason Burch, PhD, join Vineeta Agarwala, MD, PhD, general partner at a16z Bio + Health.
Together, they talk about how Ventus approaches drug discovery and why they believe we’re in the early stages of small molecule innovation. Specifically, we’ll hear about the ReSOLVE platform, which enables the drug hunting team to more accurately design and iterate on small molecular compounds for therapeutic applications. They also talk about the current candidates in the pipeline and how they’re able to go from idea to IND in record time.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
By Andreessen Horowitz, a16z Bio + Health4.6
143143 ratings
Michael Crackower, PhD, Chief Scientific Officer of Ventus Therapeutics, and Jason Burch, PhD, join Vineeta Agarwala, MD, PhD, general partner at a16z Bio + Health.
Together, they talk about how Ventus approaches drug discovery and why they believe we’re in the early stages of small molecule innovation. Specifically, we’ll hear about the ReSOLVE platform, which enables the drug hunting team to more accurately design and iterate on small molecular compounds for therapeutic applications. They also talk about the current candidates in the pipeline and how they’re able to go from idea to IND in record time.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

1,288 Listeners

537 Listeners

1,085 Listeners

2,346 Listeners

125 Listeners

321 Listeners

104 Listeners

86 Listeners

34 Listeners

25 Listeners

18 Listeners

161 Listeners

60 Listeners

57 Listeners

135 Listeners

141 Listeners

472 Listeners

35 Listeners